异烟肼联合胸腺五肽治疗复治菌阳肺结核的疗效观察

Efficacy of isoniazid combined with thymopentin in treatment of sputum positive pulmonary tuberculosis

目的探讨异烟肼联合胸腺五肽治疗复治菌阳肺结核的临床效果,为提高临床治疗菌阳肺结核患者水平。方法选取复治菌阳肺结核患者140例,随机分为对照组67例,观察组73例,对照组患者采取异烟肼、利福平、吡嗪酰胺、乙胺丁醇、链霉素联合治疗;观察组在对照组基础上加用胸腺五肽治疗,治疗期间随访痰菌阴转、病灶吸收情况,治疗后1年对两组患者治疗效果进行评价。结果治疗2、4、6、8个月时观察组患者痰菌转阴率分别为83.56%、93.15%、94.52%和95.89%,对照组分别为67.16%、74.63%、80.60%和85.07%的比例;观察组患者治疗显效达68.49%,对照组为53.73%;观察组患者治疗无效达9.59%,对照组为20.90%,两组比较差异均有统计学意义(P<0.05);患者发生不良反应对照组12例,发生率为17.91%;观察组发生不良反应13例,发生率为17.80%,两组比较差异无统计学意义。结论对复治菌阳肺结核实施异烟肼联合胸腺五肽进行治疗是一种安全而有效的治疗方法。

OBJECTIVE To investigate the clinical effect of isoniazid combined with thymopentin on the treatment ofsputum positive pulmonary tuberculosis in order to improve the clinical treatment. METHODS Totally 140 cases ofsputum positive pulmonary tuberculosis patients were randomly divided into two groups,the control group of 67cases,and 73 cases of the observation group. The control group was given isoniazid, rifampicin, pyrazinamide,and streptomycin combination therapy, and the observation group was given the thymopentin treatment, the thera-peutic effect was evaluated one year after the treatment. RESULTS The sputum negative rates 2 months, 4 months,6 months？ and 8 months after treatment of the observation group were respectively 83. 56%,93. 15%,94. 52% ,and 95. 89%,significantly higher than 67. 16%,74. 63 % , 80. 60%,and 85. 07% of the control group. The proportion of the observation group reached 68. 94%,significantly higher than 53. 73% of the control group, 9. 59%of the patients in the observation group was ineffective, significantly lower than 20. 90% in the control group, thedifference between the two groups was statistically significant （P〈0. 05）. There were 17. 91 % of the patients inthe control group, and 17. 8% of the observation group were with adverse reactions during treatment, and therewere no significent difference between the two groups. CONCLUSION Isoniazid combined with thymopentin is safeand effective in the treatment of sputum positive pulmonary tuberculosis.